Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Recruiting in Palo Alto (17 mi)

+254 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Alexion

No Placebo Group

Trial Summary

What is the purpose of this trial?

Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.

Research Team

Nuria Saval

Principal Investigator

Alexion Pharmaceuticals, Inc.

Eligibility Criteria

Inclusion Criteria

Male or female patients of any age, including minors, who have been diagnosed with aHUS

Patients with or without an identified complement pathogenic variant or anti-complement factor antibody

Able to give written informed consent. Patient or patient's parent/legal guardian must be willing and able to given written informed consent and the patient (if minor) must be willing to give written informed assent [if applicable as determined by the central Institutional Review Boards/Independent Ethics Committees (IRB/IEC)].

Treatment Details

Interventions

• Eculizumab (Monoclonal Antibodies)
• Ravulizumab (Monoclonal Antibodies)

Who Is Running the Clinical Trial?

Alexion

Lead Sponsor

Trials

247

Recruited

38,600+

Marc Dunoyer

Alexion

Chief Executive Officer since 2021

PhD in Molecular Biology, University of Brussels

Christophe Hotermans

Alexion

Chief Medical Officer since 2021

MD, University of Leuven

Alexion Pharmaceuticals, Inc.

Lead Sponsor

Trials

267

Recruited

141,000+

Dr. Alberto R. Martinez

Alexion Pharmaceuticals, Inc.

Chief Medical Officer since 2010

MD from University of Sao Paulo

Marc Dunoyer

Alexion Pharmaceuticals, Inc.

Chief Executive Officer since 2021

PhD in Molecular Biology

Alexion Pharmaceuticals

Lead Sponsor

Trials

231

Recruited

36,700+

Marc Dunoyer

Alexion Pharmaceuticals

Chief Executive Officer since 2021

B.A. in Psychology from the University of New Hampshire

Christophe Hotermans

Alexion Pharmaceuticals

Chief Medical Officer since 2023

MD

Syneos Health

Collaborator

Trials

181

Recruited

69,600+

Costa Panagos

Syneos Health

Chief Executive Officer

Bachelor's degree in a relevant field (specific details not available)

Suma Ramadas

Syneos Health

Chief Medical Officer since 2022

PhD in a relevant field (specific details not available)